Stock Scorer

InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals Inc. reported revenue of 820.2K USD for the quarter ending 31 December 2025, down 26.2% from 1.1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 820.2K -26.2%
Gross Profit Q4 '25 · ending 31 December 2025 184.2K -60.0%
Operating Income Q3 '23 · ending 30 September 2023 -2.5M —
Net Income Q1 '26 · ending 31 March 2026 -3M —
Cost of Revenue Q4 '25 · ending 31 December 2025 636K -2.3%
Operating Cash Flow Q1 '26 · ending 31 March 2026 -1.7M —
Free Cash Flow Q2 '24 · ending 30 June 2024 -1M —
Shares Outstanding Q1 '26 · ending 31 March 2026 4M +473.0%
EPS Q1 '26 · ending 31 March 2026 -2.11 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-06-30 4.9M—-8.2M-7.8M
20242024-06-30 4.6M—-7.7M-7M
20232023-06-30 4.1M-7.9M-7.9M-7.4M
20222022-06-30 1.1M-18.6M-18.6M-15.6M
20212021-06-30 1.9M-10.2M-10.2M-9.8M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262025-12-31820.2K
Q1 '262025-09-301.1M
Q4 '252025-06-301.3M
Q3 '252025-03-311.3M
Q2 '252024-12-311.1M
Q1 '252024-09-301.3M
Q4 '242024-06-301.3M
Q3 '242024-03-311.2M
Q2 '242023-12-311.2M
Q1 '242023-09-30901.9K
Q4 '232023-06-302.3M
Q3 '232023-03-311M
Q2 '232022-12-31469.8K
Q1 '232022-09-30320.8K
Q4 '222022-06-30514.8K
Q3 '222022-03-31309.6K
Q2 '222021-12-31265.1K
Q4 '212021-06-30880.6K
Q3 '212021-03-31437.3K
Q2 '212020-12-31276.8K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262025-12-31184.2K
Q1 '262025-09-30403.2K
Q4 '252025-06-30576.7K
Q3 '252025-03-31175.6K
Q2 '252024-12-31460.9K
Q1 '252024-09-30493.4K
Q4 '242024-06-30466.1K
Q3 '242024-03-31289.5K
Q2 '242023-12-31324.1K
Q1 '242023-09-3021.2K
Q4 '232023-06-301.6M
Q3 '232023-03-31192.5K
Q2 '232022-12-31131.2K
Q1 '232022-09-30-491K
Q4 '222022-06-30249.7K
Q3 '222022-03-31182.3K
Q2 '222021-12-31111.6K

Operating Income Quarterly

PeriodEndingOperating Income
Q1 '242023-09-30-2.5M
Q4 '232023-06-30-338.4K
Q3 '232023-03-31-2M
Q2 '232022-12-31-2.1M
Q1 '232022-09-30-3.5M
Q4 '222022-06-30-7.9M
Q3 '222022-03-31-3.5M
Q2 '222021-12-31-4.3M
Q1 '222021-09-30-3M
Q4 '212021-06-30-3.3M
Q3 '212021-03-31-3.1M
Q2 '212020-12-31-2.2M
Q1 '212020-09-30-1.6M

Net Income Quarterly

PeriodEndingNet Income
Q3 '262026-03-31-3M
Q2 '262025-12-31-2M
Q1 '262025-09-30-1.7M
Q4 '252025-06-30-1.8M
Q3 '252025-03-31-2.1M
Q2 '252024-12-31-2.6M
Q1 '252024-09-30-1.7M
Q4 '242024-06-30-1.9M
Q3 '242024-03-31-1.7M
Q2 '242023-12-31-1.5M
Q1 '242023-09-30-2.5M
Q4 '232023-06-30-338.4K
Q3 '232023-03-31-2M
Q2 '232022-12-31-2.1M
Q1 '232022-09-30-3.5M
Q4 '222022-06-30-7.9M
Q3 '222022-03-31-3.5M
Q2 '222021-12-31-4.3M
Q1 '222021-09-30-3M
Q4 '212021-06-30-3.3M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262025-12-31636K
Q1 '262025-09-30717K
Q4 '252025-06-30728.1K
Q3 '252025-03-311.1M
Q2 '252024-12-31650.8K
Q1 '252024-09-30771.2K
Q4 '242024-06-30817K
Q3 '242024-03-31883.1K
Q2 '242023-12-31916.1K
Q1 '242023-09-30880.6K
Q4 '232023-06-301.3M
Q3 '232023-03-31841.4K
Q2 '232022-12-31338.6K
Q1 '232022-09-30235K
Q4 '222022-06-30265K
Q3 '222022-03-31127.3K
Q2 '222021-12-31153.5K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q3 '262026-03-31-1.7M
Q2 '262025-12-31-2.4M
Q1 '262025-09-30-1.6M
Q4 '252025-06-30-1.8M
Q3 '252025-03-31-1.7M
Q2 '252024-12-31-2.5M
Q1 '252024-09-30-1.8M
Q4 '242024-06-30-1M
Q3 '242024-03-31-1.9M
Q2 '242023-12-31-1.8M
Q1 '242023-09-30-2.2M
Q4 '232023-06-30-657.9K
Q3 '232023-03-31-1.7M
Q2 '232022-12-31-2.7M
Q1 '232022-09-30-2.3M
Q4 '222022-06-30-4M
Q3 '222022-03-31-5.3M
Q2 '222021-12-31-3.5M
Q1 '222021-09-30-2.7M
Q4 '212021-06-30-2M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '242024-06-30-1M
Q3 '242024-03-31-1.9M
Q4 '222022-06-30-4M
Q3 '222022-03-31-5.4M
Q2 '222021-12-31-3.7M
Q1 '222021-09-30-2.9M
Q4 '202020-06-30-1.4M
Q3 '202020-03-31-1.5M
Q2 '202019-12-31-2.1M
Q1 '202019-09-30-2.4M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '262026-03-314M
Q2 '262025-12-314M
Q1 '262025-09-304M
Q3 '252025-03-311.1M
Q2 '252024-12-31706.5K
Q1 '252024-09-30620.1K
Q3 '242024-03-31480.6K
Q2 '242023-12-31398.7K
Q1 '242023-09-30166.4K
Q3 '232023-03-313.3M
Q2 '232022-12-312.3M
Q1 '232022-09-30865.6K
Q3 '222022-03-31566.1K
Q2 '222021-12-31553.9K
Q1 '222021-09-30481.9K
Q3 '212021-03-317.5M
Q2 '212020-12-316.1M
Q1 '212020-09-305.2M
Q3 '202020-03-315.2M
Q2 '202019-12-315.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '262026-03-31-2.11
Q2 '262025-12-31-3.32
Q1 '262025-09-30-6.45
Q4 '252025-06-30-8.72
Q3 '252025-03-31-11.95
Q2 '252024-12-31-13.59
Q1 '252024-09-30-13.66
Q4 '242024-06-30-26.19
Q3 '242024-03-31-20.21
Q2 '242023-12-31-17.23
Q1 '242023-09-30-14.43
Q4 '232023-06-30-3.25
Q3 '232023-03-31-18.61
Q2 '232022-12-31-24.15
Q1 '232022-09-30-30.97
Q4 '222022-06-30-33.08
Q3 '222022-03-31-20.45
Q2 '222021-12-31-14.72
Q1 '222021-09-30-7.36
Q4 '212021-06-30-1.50